Literature DB >> 19576336

Meta-analysis of adverse cardiovascular outcomes associated with antecedent hypertension after myocardial infarction.

Guanmin Chen1, Brenda Hemmelgarn, Sami Alhaider, Hude Quan, Norm Campbell, Doreen Rabi.   

Abstract

The aim of this study was to investigate the association of antecedent hypertension with adverse cardiovascular outcomes after myocardial infarction. A search of Medline and EMBASE was supplemented by manual searches of the bibliographies of key retrieved reports. The studies were included if they reported antecedent hypertension as a risk factor for adverse outcomes (death, stroke, congestive heart failure, recurrent myocardial infarction) in survivors of myocardial infarctions. Relative risks (RRs) were pooled using a random-effects model, and the robustness of the pooled RRs was evaluated in sensitivity analyses. Cumulative meta-analysis, by chronologic year of study beginning, was also performed. The search yielded 17 studies (n = 56,748 participants) that reported antecedent hypertension with adverse outcomes for survivors of myocardial infarctions. Randomized clinical trials (n = 8) were pooled separately from cohort studies (n = 9). For randomized clinical trials, the pooled RRs were 1.19 (95% confidence interval [CI] 1.13 to 1.26) for all-cause mortality and 1.29 (95% CI 1.09 to 1.53) for cardiovascular disease mortality. For cohort studies, the pooled RRs were 1.46 (95% CI 1.34 to 1.61) for all-cause mortality and 1.54 (95% CI 1.22 to 1.93) for cardiovascular disease mortality. Antecedent hypertension was also consistently associated with an increased risk for stroke, congestive heart failure, and recurrent myocardial infarction. Pooled estimates were robust in sensitivity analysis. In conclusion, antecedent hypertension was associated with adverse outcomes for survivors of myocardial infarctions, the association of antecedent hypertension with all-cause mortality outcomes decreased over time, and this decreased association reflects improved treatment and management of hypertension in more recent years.

Entities:  

Mesh:

Year:  2009        PMID: 19576336     DOI: 10.1016/j.amjcard.2009.02.048

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Novel mouse model of left ventricular pressure overload and infarction causing predictable ventricular remodelling and progression to heart failure.

Authors:  Carla J Weinheimer; Ling Lai; Daniel P Kelly; Attila Kovacs
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-01       Impact factor: 2.557

2.  Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.

Authors:  C Venkata S Ram; Krishnan Ramaswamy; Chunlin Qian; Joe Biskupiak; Amy Ryan; Ruth Quah; Patricia A Russo
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-10-18       Impact factor: 3.738

3.  Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence.

Authors:  Beth Sherrill; Michael Halpern; Shahnaz Khan; Jie Zhang; Sumeet Panjabi
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-11-07       Impact factor: 3.738

4.  Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction.

Authors:  Sebastian J Reinstadler; Thomas Stiermaier; Charlotte Eitel; Mohammed Saad; Bernhard Metzler; Suzanne de Waha; Georg Fuernau; Steffen Desch; Holger Thiele; Ingo Eitel
Journal:  J Cardiovasc Magn Reson       Date:  2016-11-11       Impact factor: 5.364

Review 5.  Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes.

Authors:  Jamie L Benham; Jane E Booth; Ronald J Sigal; Stella S Daskalopoulou; Alexander A Leung; Doreen M Rabi
Journal:  Int J Cardiol Heart Vasc       Date:  2021-02-10

6.  Effect of long-term resistance exercise on body composition, blood lipid factors, and vascular compliance in the hypertensive elderly men.

Authors:  Hyun-Sub Kim; Dae-Geun Kim
Journal:  J Exerc Rehabil       Date:  2013-04-25

7.  Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial Infarction.

Authors:  David Carrick; Caroline Haig; Annette M Maznyczka; Jaclyn Carberry; Kenneth Mangion; Nadeem Ahmed; Vannesa Teng Yue May; Margaret McEntegart; Mark C Petrie; Hany Eteiba; Mitchell Lindsay; Stuart Hood; Stuart Watkins; Andrew Davie; Ahmed Mahrous; Ify Mordi; Ian Ford; Aleksandra Radjenovic; Paul Welsh; Naveed Sattar; Kirsty Wetherall; Keith G Oldroyd; Colin Berry
Journal:  Hypertension       Date:  2018-09       Impact factor: 10.190

8.  Impact of pharmacological treatment of diabetes mellitus on dementia risk: systematic review and meta-analysis.

Authors:  Jacqueline M McMillan; Bria S Mele; David B Hogan; Alexander A Leung
Journal:  BMJ Open Diabetes Res Care       Date:  2018-11-16

9.  Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting.

Authors:  Zhe Liang; Qi Chen; Ruiqi Wei; Chenyao Ma; Xuehui Zhang; Xue Chen; Fang Fang; Quanming Zhao
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.